ClinConnect ClinConnect Logo
Search / Trial NCT06457945

Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions

Launched by HOSPICES CIVILS DE LYON · Jun 11, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is investigating how mind-wandering affects people with narcolepsy type 1 (NT1) and other sleep disorders. Mind-wandering is when our attention drifts away from what we're currently doing to focus on our thoughts, memories, or future plans. Researchers want to understand if this state, which can occur more often in people with NT1 because of unexpected sleep-like experiences during the day, impacts their ability to perform tasks that require focus and learning. They will compare NT1 patients to those with idiopathic hypersomnia (IH) and those without any sleep disorders to see how mind-wandering influences their cognitive skills, like learning new information.

To participate in this trial, individuals aged 18 to 65 who have been diagnosed with NT1 or IH may be eligible, provided they meet specific criteria, such as having a certain level of sleepiness on a test. Participants can expect to engage in tasks that assess their cognitive abilities while researchers monitor their mind-wandering and sleep patterns. It’s important to note that individuals with certain cognitive impairments, untreated sleep apnea, or those taking specific medications may not be eligible to join. This study aims to shed light on how sleep and attention interact, helping improve understanding and treatment of sleep disorders.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with NT1 or IH diagnosis according to ICSD3-TR criteria (American Academy of Sleep, 2023)
  • For patient with IH: with abnormal Mean Sleep Latency Test (MSLT) (mean latency ≤ 8 min, ≤ 1 SOREMp)
  • Patients with subjective hypersomnolence without underlying cause (negative extensive work-up including actigraphy, PSG, MSLT, 24h bedrest, biological tests, MRI, psychiatric consultation; this allows to rule out sleep deprivation, irregular sleep/wake schedule, sleep apnea or other sleep disorders associated with sleep fragmentation, somatic/psychiatric causes of hypersomnolence, sedative substance intake). This type of "controls" have already been used in studies on hypersomnolence disorders.
  • Exclusion Criteria:
  • Cognitive impairment not compatible with the task
  • Treatment with antidepressant
  • Other cause of hypersomnolence: untreated severe obstructive sleep apnea, sleep-wake circadian rhythm disorders, sleep deprivation, somatic/psychiatric causes of hypersomnolence, sedative substance intake
  • Unstable medical or psychiatric condition
  • Refusal to participate

About Hospices Civils De Lyon

Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.

Locations

Lyon, , France

Patients applied

0 patients applied

Trial Officials

Laure PETER-DEREX, Professor

Principal Investigator

Hospices Civils de Lyon

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported